cartilage-derived inhibitor

cartilage-derived inhibitor

Fringe oncology
An angiogenic macroprotein abundant in shark cartilage, which allegedly decreased tumour formation in sharks.
 
Molecular medicine
A natural anti-angiogenesis factor for treating solid tumours, which was being developed in the mid-1990s by Boston Life Sciences. The data on the efficacy of cartilage proved compellingly underwhelming enough that all work on developing such products for treating cancer was abandoned.
Mentioned in ?
References in periodicals archive ?
BLSI's products in pre-clinical development or in clinical trials include, among others, THERAFECTIN(R) (amiprilose HCl), a potential treatment for rheumatoid arthritis; Cartilage-derived Inhibitor (CDI), a natural anti-angiogenesis factor to treat solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; and transcription factors that control the expression of molecules associated with autoimmune disease and allergies.
BLSI's products in clinical trials or in pre-clinical development include Cartilage-derived Inhibitor (CDI), a natural anti-angiogenesis factor for the treatment of solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; Altropane(TM), a radioimaging agent for the diagnosis of Parkinson's Disease; THERAFECTIN(R) for the treatment of Rheumatoid Arthritis; and a different transcription factor that controls the expression of molecules associated with autoimmune disease.
BLSI's products include, among others, THERAFECTIN(R) (amiprilose HCl), a potential treatment for rheumatoid arthritis; Cartilage-Derived Inhibitor (CDI), a natural anti-angiogenesis factor for the treatment of solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; Altropane(TM), a radioimaging agent for the diagnosis of Parkinson's Disease; and a transcription factor that controls the expression of molecules associated with autoimmune disease.
In addition to THERAFECTIN, BLSI's products include Cartilage-derived Inhibitor (CDI), a natural anti-angiogenesis factor for the treatment of solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; Altropane(TM), a radioimaging agent for the diagnosis of Parkinson's Disease; and a transcription factor that controls the expression of molecules associated with autoimmune disease.
BLSI's products include, among others, THERAFECTIN(R) (amiprilose HCI), a potential treatment for rheumatoid arthritis; Cartilage-derived Inhibitor (CDI), a natural anti-angiogenesis factor for the treatment of solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; Altropane(TM), a radioimaging agent for the diagnosis of Parkinson's Disease; and a transcription factor that controls the expression of molecules associated with autoimmune disease.
BLSI's products include, among others, THERAFECTIN(R) (amiprilose HC1), a potential treatment for rheumatoid arthritis; Cartilage-Derived Inhibitor (CDI), a natural anti-angiogenesis factor to treat solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; and a transcription factor that controls the expression of molecules associated with autoimmune disease.
BLSI's products include among others, Cartilage-derived Inhibitor (CDI), a natural anti-angiogensis factor for the treatment of solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; Altropane(TM), a radioimaging agent for the diagnosis of Parkinson's Disease; and a transcription factor that controls the expression of molecules associated with autoimmune disease.

Full browser ?